Sihuan Pharmaceutical Holdings Group Ltd. is a leading pharmaceutical company and the largest cardio-cerebral vascular drug franchise in China by market share. The success of our company can be attributed to our portfolio of market leading drugs, unique marketing model, extensive nationwide distribution network and strong research and development capabilities.

Sihuan Pharmaceutical currently has 87 products encompassing the top five medical therapeutic areas in China: cardiovascular system, nervous system, anti-infective, metabolism, and oncology. Our major products such as Kelinao, Anjieli, Chuanqing, Quao and Aogan are widely used in the treatment of various cardio-cerebral vascular diseases. Kelinao and Anjieli, in particular, have been the top two bestsellers among hospitals each year since 2007.

Our successful sales and marketing model is unique and is underpinned by an extensive network of over 2,000 distributors covering close to 10,000 hospitals and medical institutions across China.

Our strengths in research and development provide us with an edge in developing new drugs and first-to-market generic drugs. Our drug research and development team, one of the largest in China, focuses on developing first-to-market generic drugs and innovative drugs that meet market demand. We continually expand and enhance our portfolio of products by making use of our proven multiple channel strategy that includes acquisition. We have a track record of successfully identifying and acquiring products, and the products acquired by us have been developed into market leaders.

We produce our drugs through six integrated production facilities under the most stringent quality control conditions. To capitalize on growing demand in the market we are planning to expand our production capacity. The expansion is expected to help further ensure stable product supply while enhancing our abilities to control costs and product quality.

Taking advantage of China's growing economy and ongoing healthcare reforms, we will actively seek to secure long-term growth opportunities for the Group by taking steps to expand our marketing and distribution network, enhance research and development, optimize production capacity, and further improve our product portfolio. Our mission is to be an international leader in the development and marketing of cardio-cerebral vascular drugs and to provide the best pharmaceutical products to patients.

Our History

	Hainan Sihuan was founded
	Kelinao approved
	Acquired 28% interest in Beijing Sihuan Launched Kelinao and Chuanqing
	Granted a 20-year patent for the chemical synthesis process for Cinepazide Maleate (API of Kelinao)
	Entered into a JV to establish Hainan Sihuan CVD Research
	Beijing Sihuan became the wholly owned subsidiary of the Company
	Achieved #1 CCV market share for the first time Sihuan was listed in Singapore on 23 March 2007
	Acquired 60% interest in KBP BioSciences Launched Aogan
	Launched Qingtong Delisted from Singapore
	Listed on the mainboard of Hong Kong Stock Exchange Acquired 100% interests of Dupromise Acquired the 30-year exclusive distribution rights for Alprostadil Key products acquired: - Aodimei (Cerebroside-Kinin Injection) - Yuanzhijiu (Troxerutin and Cerebroprotein Hydrolysate Injection) - Fufangsanwei B Injection (II) (Compound Trivitamin B for Injection (II)) - Yimaining ( Alprostadil lipid emulsion Injection)
	Acquired 80% interest of Changchun Xiangtong Pharmaceutical Acquired 100% interests of Vinise Pharmaceutical，Disposed 50% equity interest in Vinise Pharmaceutical to ShandongBuchang Pharmaceutical Key products acquired: - GM1 injections and API - Breviscapine and Sodium Chloride injections - Scutellarin Glucose injections - Salviae Miltiorrhizae and Ligustrazine injections - Salivae Miltiorrhizae Liguspyragine Hydrochloride and Glucose injections